Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tricomin is a topical cosmeceutical product line designed to treat hair loss and thinning hair in both men and women. Its primary active ingredient is the **Triamino Copper Complex** (AHK-Cu), a patented blend of copper and amino acids. The mechanism of action involves enhancing follicle health and scalp function; copper peptides are believed to stimulate follicle activity and potentially inhibit **5-alpha reductase**, the enzyme responsible for converting testosterone into dihydrotestosterone (DHT), a key factor in androgenetic alopecia. Originally developed by **Procyte Corporation** and currently marketed by **NEOVA SmartSkincare**, Tricomin has undergone Phase II clinical trials demonstrating efficacy in improving hair density and follicle health. It is typically formulated as a follicle spray, shampoo, or conditioner.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tricomin.